OPKO Health (NASDAQ:OPK) Director Robert Scott Fishel bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The stock was bought at an average cost of $3.02 per share, for a total transaction of $30,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:OPK opened at $3.02 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.98 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1,672.83, a price-to-earnings ratio of -10.41 and a beta of 1.56. OPKO Health has a 52 week low of $2.66 and a 52 week high of $7.90.

How to Become a New Pot Stock Millionaire

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The business had revenue of $193.70 million for the quarter, compared to the consensus estimate of $307.44 million. OPKO Health had a negative net margin of 28.93% and a negative return on equity of 7.87%. analysts predict that OPKO Health will post -0.48 earnings per share for the current fiscal year.

A number of equities analysts recently commented on OPK shares. BidaskClub cut OPKO Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 10th. Zacks Investment Research cut OPKO Health from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. ValuEngine cut OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $20.00 target price on OPKO Health and gave the stock a “buy” rating in a report on Thursday, March 1st. Finally, JPMorgan Chase cut OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price on the stock. in a report on Friday, March 2nd. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $11.29.

A number of large investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB bought a new stake in OPKO Health during the fourth quarter valued at about $179,000. Delek Group Ltd. bought a new stake in OPKO Health during the fourth quarter valued at about $382,000. Meitav Dash Investments Ltd. bought a new stake in OPKO Health during the fourth quarter valued at about $347,000. Belpointe Asset Management LLC raised its holdings in OPKO Health by 30.0% during the fourth quarter. Belpointe Asset Management LLC now owns 110,500 shares of the biotechnology company’s stock valued at $541,000 after acquiring an additional 25,500 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. raised its holdings in OPKO Health by 18.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 340,326 shares of the biotechnology company’s stock valued at $1,668,000 after acquiring an additional 51,890 shares during the period. 23.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Insider Buying: OPKO Health (OPK) Director Acquires 10,000 Shares of Stock” was reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/04/17/insider-buying-opko-health-opk-director-acquires-10000-shares-of-stock.html.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.